CERAMENT® V (Vancomycin)
Chronic osteomyelitis (bone infection), particularly gentamicin-resistant cases
Approved/CommercialMarketed (EU), Development (US)
Key Facts
Indication
Chronic osteomyelitis (bone infection), particularly gentamicin-resistant cases
Phase
Approved/Commercial
Status
Marketed (EU), Development (US)
Company
About Bonesupport Holding AB
Bonesupport Holding AB is a commercial-stage orthobiologics company focused on improving outcomes in bone infection and complex trauma through its proprietary CERAMENT® technology platform. The company's core innovation is an injectable, osteoconductive calcium sulfate/hydroxyapatite bone graft that can be loaded with antibiotics for local delivery. With regulatory approvals in key markets and a growing commercial footprint, Bonesupport aims to become a leader in the management of bone infections and complex fractures, leveraging clinical data demonstrating reduced infection recurrence and improved healing.
View full company profile